Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol | Zendy

MaryAnn Zhang | Zendy; Daniel H. Solomon | Zendy; Rishi Desai | Zendy; Eun Ha Kang | Zendy; Jun Liu | Zendy; Tuhieogi | Zendy; Seoyoung C. Kim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol

Author(s) -

MaryAnn Zhang,

Daniel H. Solomon,

Rishi Desai,

Eun Ha Kang,

Jun Liu,

Tuhieogi,

Seoyoung C. Kim

Publication year - 2018

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.118.033992

Subject(s) - medicine , febuxostat , allopurinol , gout , hazard ratio , hyperuricemia , myocardial infarction , propensity score matching , stroke (engine) , proportional hazards model , cardiology , surgery , uric acid , confidence interval , mechanical engineering , engineering

Hyperuricemia and gout are associated with an increased risk of cardiovascular disease. Xanthine oxidase inhibitors, allopurinol and febuxostat, are the mainstay of urate-lowering treatment for gout and may have different effects on cardiovascular risk in patients with gout.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research